155P Safety and efficacy of niraparib in Japanese recurrent ovarian cancer patients: Maintenance therapy for platinum-sensitive recurrence and late-line monotherapy

Real-world data on niraparib in Japanese patients are limited. This interim analysis describes patient characteristics, treatment status, and safety outcomes during the first 6 months of niraparib therapy.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108202
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

155P Safety and efficacy of niraparib in Japanese recurrent ovarian cancer patients: Maintenance therapy for platinum-sensitive recurrence and late-line monotherapy

T. Chiyoda, M. Shimada, H. Kobara, H. Kajiyama et al.
ESMO Open
PARP inhibition in cancer therapy
article

155P Safety and efficacy of niraparib in Japanese recurrent ovarian cancer patients: Maintenance therapy for platinum-sensitive recurrence and late-line monotherapy

T. Chiyoda, M. Shimada, H. Kobara, H. Kajiyama, T. Kuroda, H. Nomura, S. Shigeta, K. Yokosu, H. Nakai, R. Murakami, M. Kamata, T. Kagimura, A. Kato, Y. Takei, A. Okamoto, S. Fujiwara, T. Ohta
article en

Abstract

Real-world data on niraparib in Japanese patients are limited. This interim analysis describes patient characteristics, treatment status, and safety outcomes during the first 6 months of niraparib therapy.

ESMO OpenVol. 11
Yamagata University (JP), Jikei University School of Medicine (JP), Tokai University (JP), Shinshu University (JP), Jichi Medical University (JP), Tohoku University (JP), Keio University (JP), Osaka Medical and Pharmaceutical University (JP), Kyoto University (JP), Tohoku University Hospital (JP), Kindai University Hospital (JP), Jichi Medical University Hospital (JP), Foundation for Biomedical Research and Innovation (JP), Japanese Foundation For Cancer Research (JP), Takeda (Japan) (JP), Nagoya University (JP), Kindai University (JP)
Good health and well-being
Openalex Percentile: Top 8%
PARP inhibition in cancer therapy
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

155P Safety and efficacy of niraparib in Japanese recurrent ovarian cancer patients: Maintenance therapy for platinum-sensitive recurrence and late-line monotherapy — T. Chiyoda, M. Shimada, et al. · ESMO Open (2026) | TGRS Research Map | TGRS